206 related articles for article (PubMed ID: 22508928)
1. Novel role for surfactant protein A in gastrointestinal graft-versus-host disease.
Gowdy KM; Cardona DM; Nugent JL; Giamberardino C; Thomas JM; Mukherjee S; Martinu T; Foster WM; Plevy SE; Pastva AM; Wright JR; Palmer SM
J Immunol; 2012 May; 188(10):4897-905. PubMed ID: 22508928
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin attenuates acute gastrointestinal graft-versus-host disease by preventing apoptosis of intestinal epithelial cells.
Kawakami K; Minami N; Matsuura M; Iida T; Toyonaga T; Nagaishi K; Arimura Y; Fujimiya M; Uede T; Nakase H
Biochem Biophys Res Commun; 2017 Apr; 485(2):468-475. PubMed ID: 28192120
[TBL] [Abstract][Full Text] [Related]
3. Donor T-Cell Repertoire Profiling in Recipient Lymphoid and Parenchyma Organs Reveals GVHD Pathogenesis at Clonal Levels After Bone Marrow Transplantation in Mice.
Wu Y; Fu J; Wang H; Yu XZ
Front Immunol; 2021; 12():778996. PubMed ID: 34950143
[TBL] [Abstract][Full Text] [Related]
4. Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model).
Azar Y; Shainer R; Almogi-Hazan O; Bringer R; Compton SR; Paidas MJ; Barnea ER; Or R
Biol Blood Marrow Transplant; 2013 Apr; 19(4):519-28. PubMed ID: 23266739
[TBL] [Abstract][Full Text] [Related]
5. Surfactant protein A is a required mediator of keratinocyte growth factor after experimental marrow transplantation.
Haddad IY; Milla C; Yang S; Panoskaltsis-Mortari A; Hawgood S; Lacey DL; Blazar BR
Am J Physiol Lung Cell Mol Physiol; 2003 Sep; 285(3):L602-10. PubMed ID: 12740217
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation.
Shankar G; Bryson JS; Jennings CD; Morris PE; Cohen DA
Am J Respir Cell Mol Biol; 1998 Feb; 18(2):235-42. PubMed ID: 9476911
[TBL] [Abstract][Full Text] [Related]
7. Host MyD88 signaling protects against acute graft-versus-host disease after allogeneic bone marrow transplantation.
Xing S; Zhang X; Liu JH; Huang X; Zhou P
Clin Exp Immunol; 2019 Jan; 195(1):121-131. PubMed ID: 30317551
[TBL] [Abstract][Full Text] [Related]
8. [An absence of donor TH17 differentiation ameliorates dermal tissue damage].
Cheng H; Song GL; Pan B; Tian J; Yan ZL; Chen W; Xu KL; Li ZY; Zeng LY
Zhonghua Yi Xue Za Zhi; 2011 Jul; 91(26):1843-6. PubMed ID: 22093788
[TBL] [Abstract][Full Text] [Related]
9. IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.
Sun K; Hsiao HH; Li M; Ames E; Bouchlaka M; Welniak LA; Hagino T; Jagdeo J; Pai CC; Chen M; Blazar BR; Abedi M; Murphy WJ
J Immunol; 2012 Aug; 189(4):2033-42. PubMed ID: 22778394
[TBL] [Abstract][Full Text] [Related]
10. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
[TBL] [Abstract][Full Text] [Related]
11. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
12. Recipient mucosal-associated invariant T cells control GVHD within the colon.
Varelias A; Bunting MD; Ormerod KL; Koyama M; Olver SD; Straube J; Kuns RD; Robb RJ; Henden AS; Cooper L; Lachner N; Gartlan KH; Lantz O; Kjer-Nielsen L; Mak JY; Fairlie DP; Clouston AD; McCluskey J; Rossjohn J; Lane SW; Hugenholtz P; Hill GR
J Clin Invest; 2018 May; 128(5):1919-1936. PubMed ID: 29629900
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow deficient in IFN-{gamma} signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect.
Capitini CM; Herby S; Milliron M; Anver MR; Mackall CL; Fry TJ
Blood; 2009 May; 113(20):5002-9. PubMed ID: 19258593
[TBL] [Abstract][Full Text] [Related]
14. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
[TBL] [Abstract][Full Text] [Related]
15. Fas-deficient lpr mice are more susceptible to graft-versus-host disease.
van Den Brink MR; Moore E; Horndasch KJ; Crawford JM; Hoffman J; Murphy GF; Burakoff SJ
J Immunol; 2000 Jan; 164(1):469-80. PubMed ID: 10605044
[TBL] [Abstract][Full Text] [Related]
16. Secondary lymphoid organs contribute to, but are not required for the induction of graft-versus-host responses following allogeneic bone marrow transplantation: a shifting paradigm for T cell allo-activation.
Silva IA; Olkiewicz K; Askew D; Fisher JM; Chaudhary MN; Vannella KM; Deurloo DT; Choi SW; Pierce EM; Clouthier SG; Liu C; Cooke KR
Biol Blood Marrow Transplant; 2010 May; 16(5):598-611. PubMed ID: 20117226
[TBL] [Abstract][Full Text] [Related]
17. T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease.
Iclozan C; Yu Y; Liu C; Liang Y; Yi T; Anasetti C; Yu XZ
Biol Blood Marrow Transplant; 2010 Feb; 16(2):170-8. PubMed ID: 19804837
[TBL] [Abstract][Full Text] [Related]
18. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JL
J Clin Invest; 1999 Aug; 104(4):459-67. PubMed ID: 10449438
[TBL] [Abstract][Full Text] [Related]
19. IFN-λ therapy prevents severe gastrointestinal graft-versus-host disease.
Henden AS; Koyama M; Robb RJ; Forero A; Kuns RD; Chang K; Ensbey KS; Varelias A; Kazakoff SH; Waddell N; Clouston AD; Giri R; Begun J; Blazar BR; Degli-Esposti MA; Kotenko SV; Lane SW; Bowerman KL; Savan R; Hugenholtz P; Gartlan KH; Hill GR
Blood; 2021 Aug; 138(8):722-737. PubMed ID: 34436524
[TBL] [Abstract][Full Text] [Related]
20. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
